ESC 365 - Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial

ESC Professional Premium Access

Efficacy and safety of sacubitril/valsartan according to frailty in heart failure with preserved ejection fraction: a post hoc analysis of the PARAGON-HF trial

Session: How to treat HFpEF in 2022 and beyond

Topic: Comorbidities

Speaker: Doctor J. Butt (Copenhagen, DK)

Event: ESC Congress 2022

Congress Presentation

Add to my library

About the speaker

Doctor Jawad Haider Butt

Rigshospitalet - Copenhagen University Hospital, Copenhagen (Denmark)

1 presentation

0 follower

3 more presentations in this session

Treating HFpEF: State of the art 2022

Speaker: Professor S. Solomon (Boston, US)

Efficacy of empagliflozin in patients with heart failure according to baseline KDIGO risk categories - findings from the EMPEROR-Pooled

Speaker: Professor J. Butler (Dallas, US)

Digoxin improves systolic cardiac function in patients with AF and HFpEF: the RATE-AF randomised trial

Speaker: Doctor K. Bunting (Birmingham, GB)

Access the full session

How to treat HFpEF in 2022 and beyond

Speakers: Doctor J. Butt, Professor S. Solomon, Professor J. Butler, Doctor K. Bunting

About the event

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources

Explore sponsored resources